• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis.
CONCLUSIONS: According to the results of this analysis, DAPT might have to be cautiously be used following PCI in a population of patients with thrombocytopenia at baseline due to the significantly higher bleeding rate including gastro-intestinal, intra-cranial bleeding and hemorrhagic stroke. Hence, special care might have to be taken when considering anti-platelet agents following PCI in these high risk patients. However, considering the present limitations of this analysis, this hypothesis will have to be confirmed in future trials. PMID: 32334636 [PubMed - as supplied by publisher]
Source: BMC Pharmacology and Toxicology - April 27, 2020 Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research

Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials
Aimed to evaluate and compare the interactive effects of different antiplatelet or anticoagulation strategies in patients with chronic coronary syndromes (CCS) after percutaneous coronary intervention (PCI). Randomized controlled trials comparing different antiplatelet or anticoagulant strategies in patients with CCS after PCI were included. The primary outcomes were major adverse cardiovascular event (MACE), mortality, ischemic and bleeding events. Compared to aspirin alone, addition of prasugrel or ticagrelor to aspirin resulted in lower risk of myocardial infarction (MI) [odds ratio (OR): 0.38 (95% confidence interval 0...
Source: Frontiers in Pharmacology - September 30, 2022 Category: Drugs & Pharmacology Source Type: research

Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
ConclusionsThe utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Source: European Journal of Clinical Pharmacology - February 24, 2023 Category: Drugs & Pharmacology Source Type: research

P2Y12 receptor antagonists: which one to choose? A systematic review and meta-analysis.
Conclusion: Newer P2Y12 receptor antagonists are associated with better cardiovascular outcomes in patients with ACS and/or undergoing PCI. Prasugrel use resulted in higher major bleeding rates and no overall mortality benefit compared with clopidogrel. PMID: 27290917 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 7, 2016 Category: Drugs & Pharmacology Authors: Briasoulis A, Telila T, Palla M, Siasos G, Tousoulis D Tags: Curr Pharm Des Source Type: research

Oral Anticoagulants With Dual Antiplatelet Therapy Versus Clopidogrel in Patients After Percutaneous Coronary Intervention: A Meta-Analysis
Conclusions: In patients who are on OAC with vitamin K antagonist and underwent percutaneous coronary intervention, no significant differences were found in mortality, ischemic, and hemorrhagic complications between the patients treated with TT and DT. Thus, tailored treatment based on individual thromboembolic and bleeding risk might be the most reasonable approach in these patients.
Source: American Journal of Therapeutics - December 29, 2018 Category: Drugs & Pharmacology Tags: Reviews Source Type: research

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
In conclusion, the present study identified canagliflozin as a potent inhibitor of human EC proliferation. The anti-proliferative action of canagliflozin is observed in ECs isolated from both the venous and arterial circulation, and is partly due to the blockade of cyclin A expression. In addition, this study found that canagliflozin inhibits tube formation in cultured ECs and mouse aortic rings. Notably, these actions are specific for canagliflozin and not seen with other SGLT2 inhibitors. The ability of canagliflozin to exert these pleiotropic effects on EC function may contribute to both the adverse and salutary actions...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome and percutaneous coronary intervention.
Authors: Gumprecht J, Domek M, Lip GY Abstract Introduction: The non-vitamin K antagonist oral anticoagulants (NOACs) are changing the landscape for stroke prevention in atrial fibrillation (AF) and prevention or treatment of venous thromboembolism (VTE). In patients with AF and concomitant acute coronary syndrome (ACS), the treatment regimen of combined NOACs and P2Y12 inhibitors is gaining popularity. Areas covered: The authors conducted a review of studies published in the last 10 years regarding safety evaluation and effectiveness of apixaban for the treatment of AF and ACS, both alone and in combination with d...
Source: Expert Opinion on Drug Safety - October 4, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
CONCLUSION: The TA treatment in the European and American populations is more beneficial and safer than CA treatment. However, although the Asian population has this benefit, the risk of bleeding is significantly increased as well, and care should be taken when choosing antiplatelet drugs. PMID: 32534561 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 13, 2020 Category: Drugs & Pharmacology Authors: Wu H, Xiang X, Li D, Shen S, Li X Tags: Curr Pharm Des Source Type: research

Efficacy and safety of ticagrelor monotherapy in patients undergoing percutaneous coronary intervention: a meta-analysis
Clin Pharmacol Ther. 2021 Mar 5. doi: 10.1002/cpt.2226. Online ahead of print.ABSTRACTDual antiplatelet therapy (DAPT) and subsequent P2Y12 inhibitor monotherapy, particularly ticagrelor, is an emerging treatment strategy in patients undergoing percutaneous coronary intervention (PCI). This meta-analysis was designed to investigate whether short-term DAPT followed by ticagrelor monotherapy is associated with a favorable outcome as compared to standard DAPT. 1-3 months of DAPT was termed "short-term" DAPT, 6-12 months DAPT was termed "standard" DAPT. The primary outcome was the composite of major adverse cardiovascular even...
Source: Clinical Pharmacology and Therapeutics - March 5, 2021 Category: Drugs & Pharmacology Authors: Georg Gelbenegger Christian Schoergenhofer Bernd Jilma Gloria M Gager Al Medina Dizdarevic Mamas A Mamas Biljana Parapid Poonam Velagapudi Jolanta M Siller-Matula Source Type: research

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice
CONCLUSIONS: The treatment of bivalirudin showed better efficacy and safety as compared to UFH among patients with ACS undergoing PCI at high risk of bleeding in contemporary practice.PMID:34321166 | DOI:10.1016/j.biopha.2020.110758
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 29, 2021 Category: Drugs & Pharmacology Authors: Yahao Zhang Yanghui Zhang Zhiyu Liu Bin Zhang Guizhi Liu Kui Chen Source Type: research

Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-site, Real-world Investigation
The objective of this study was to validate the ability of ABCD-GENE score to predict risk for atherothrombotic events in a diverse, real-world population of clopidogrel-treated PCI patients who received clinical CYP2C19 genotyping to guide antiplatelet therapy. A total of 2341 adult patients who underwent PCI, were genotyped for CYP2C19, and received treatment with clopidogrel across four institutions were included (mean age 64±12 years, 35% female, 20% Black). The primary outcome was major atherothrombotic events, defined as the composite of all-cause death, myocardial infarction, ischemic stroke, stent thrombosis, or r...
Source: Clinical Pharmacology and Therapeutics - April 16, 2022 Category: Drugs & Pharmacology Authors: Cameron D Thomas Francesco Franchi Ellen C Keeley Joseph S Rossi Marshall Winget R David Anderson Alyssa L Dempsey Yan Gong Megan N Gower Richard A Kerensky Natasha Kulick Jean G Malave Caitrin W McDonough Ian R Mulrenin Petr Starostik Amber L Beitelshees Source Type: research

Efficacy and safety of direct oral anticoagulants in the treatment of left ventricular thrombus after acute anterior myocardial infarction in patients who underwent percutaneous coronary intervention
CONCLUSIONS: DOACs appears to be a suitable alternative to warfarin for the management of LVT post STEMI, especially in patients who are intolerant to warfarin.PMID:36200193 | DOI:10.2174/1570161120666221003104821
Source: Current Vascular Pharmacology - October 6, 2022 Category: Drugs & Pharmacology Authors: Jing Liang Zhijian Wang Yujie Zhou Hua Shen Meng Chai Xiaoteng Ma Hongya Han Qiaoyu Shao Qiuxuan Li Source Type: research

Pages: 1  2  3  4